BVXP Bioventix Plc

 
TIDMBVXP 
 
Bioventix plc 
 
                        ("Bioventix" or the "Company") 
 
                   Trading Update, Notice of Results and AGM 
 
Trading Update 
 
Bioventix plc (BVXP), a UK company specialising in the development and 
commercial supply of high-affinity monoclonal antibodies for application in 
clinical diagnostics, announces a trading update. 
 
The Board is pleased to report that revenues for the financial year ended 30 
June 2017 are expected to be marginally in excess of GBP7M (2015/16: GBP5.5M). 
Since the cost-base of the Company continues to follow a similar shallow 
trajectory as in previous years, both revenues and profits before tax are 
expected to be ahead of market expectations for the year ended 30 June 2017. 
 
Notice of Results 
 
The audited accounts for the year ended 30 June 2017 are due to be released on 
Monday 17 October 2017. We will comment on the revenues in more detail at this 
time. 
 
AGM 
 
The Bioventix AGM will be held at 2pm on Thursday 14th December at Farnham 
Castle (GU9 0AG) 
 
The information communicated in this announcement contains inside information 
for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014. 
 
For further information please contact: 
 
Bioventix plc                                     Tel: 01252 728 001 
Peter Harrison           Chief Executive Officer 
 
finnCap Ltd                                       Tel: 020 7220 0500 
Geoff Nash/Simon Hicks   Corporate Finance 
Stephen Norcross         Corporate Broking 
 
About Bioventix plc: 
 
Bioventix (www.bioventix.com) specialises in the development and commercial 
supply of high-affinity monoclonal antibodies with a primary focus on their 
application in clinical diagnostics, such as in automated immunoassays used in 
blood testing. The antibodies created at Bioventix are generated in sheep and 
are of particular benefit where the target is present at low concentration and 
where conventional monoclonal or polyclonal antibodies have failed to produce a 
suitable reagent. Bioventix currently offers a portfolio of antibodies to 
customers for both commercial use and R&D purposes, for the diagnosis or 
monitoring of a broad range of conditions, including heart disease, cancer, 
fertility, thyroid function and drug abuse. Bioventix currently supplies 
antibody products and services to the majority of multinational clinical 
diagnostics companies. Bioventix is based in Farnham, UK and its shares are 
traded on AIM under the symbol BVXP. 
 
 
 
END 
 

(END) Dow Jones Newswires

September 04, 2017 02:00 ET (06:00 GMT)

Bioventix (LSE:BVXP)
Historical Stock Chart
From Apr 2024 to May 2024

Bioventix (LSE:BVXP)
Historical Stock Chart
From May 2023 to May 2024